The best tool you have for demonstrating the value of your therapies is your patients—what they say about the compounded medications you dispense to them.
In a Sep 16 letter to NABP CEO Al Carter, FDA states that DTE products “can put patients at harm” and that “therapies containing DTE are biological products subject to licensure under Section 351(i) of the PHS Act.”
If patient-reported outcomes can prove your value, why aren’t more of you collecting them?
One result of last week’s Compounders on Capitol Hill visits has been the creation of a joint congressional letter to FDA’s Center for Veterinary Medicine raising concerns about the great ambiguity in GFI 256 on animal compounding
Express Scripts (ESI) has slashed pharmacy reimbursements for 2023, making it impossible for many independent community pharmacies to participate in the TRICARE pharmacy network.
What if APC gave you a tool that would meet state and accreditation requirements that you have a continuous quality improvement program?
One result of last week’s Compounders on Capitol Hill has been the creation of a joint congressional letter to FDA’s Center for Veterinary Medicine raising concerns about the great ambiguity in GFI 256 on animal compounding,
A.J. Day, vice president of clinical services at PCCA, and an APC Board member, was named APC’s 2022 George and Lucy Malmberg Compounding Advocacy Champion during Compounders on Capitol Hill.
Please join us in congratulating the 2022 APC Fellows...
At APC, we are always working on our members' behalf.
This coming Thursday, September 15—the same day as our Congressional visits in DC—is Compounding Advocacy Day.
To help you educate your prescribers, APC and the Pharmacy Compounding Foundation have developed three member-only briefing documents you can share with physicians and other medical professionals.
Thanks to generous support from the Pharmacy Compounding Foundation, our Campaign to Save Compounded Hormones is being featured in Politico.com.
We’re pleased to welcome our newest PFM members to the fold, bringing the total to 63 pharmacies and facilities that have joined APC as PFMs since March.
September 15 is Compounding Advocacy Day, and you have two ways to participate…
Shipment Trackers, APC's newest Pharmacy/Facility Member (PFM) affinity service provider, offers preferred pricing on several services to PFMs.
In an APC member survey conducted last month, 59% of compounders said they were not aware that FDA’s Guidance for Industry #256 is slated to be enforced beginning October 1, 2022.
Earlier this week, APC submitted a letter signed by nearly 2,000 prescribers of compounded hormones to FDA Commissioner Robert Califf, urging FDA to assure continued patient access to compounded hormone therapy.
FDA’s director of the Office of Compounding Quality and Compliance, Gail Bormel, has accepted APC’s invitation to attend Compounders on Capitol Hill.
Help us help YOU get ready for GFI #256 by taking a quick survey.
A letter signed by 1,957 prescribers of compounded hormones was submitted this week to FDA Commissioner Robert Califf urging that he preserve continued patient access to compounded hormone therapy.
Maybe you’ve heard about FDA’s GFI 256, regarding animal compounding, and wondered if it might affect mew.
Please take our survey regarding GFI 256.
Here are five compelling reasons you should join us in DC next month...
3,222 folks have sent 9,370 cBHT messages to 269 members of Congress.
Yesterday, APC’s cBHT Campaign Steering Committee hosted an emergency briefing for APC members and compounding supporters and made three urgent asks of them.
We’re conducting a survey of compounding pharmacies to help APC understand your readiness for compliance with GFI #256 so that we can advise FDA about whether an enforcement delay is warranted.
Don't wait too much longer to register for CCH 2022, as the APC room block at the Hilton National Mall is filling up fast, and there’s no overflow hotel.
As required under its Bylaws, the 2022 annual meeting of the Alliance for Pharmacy Compounding will be held on Wednesday, September 14, 2:00-2:30pm.
Congressman Buddy Carter (GA) and Congresswoman Diana Harshbarger (TN) respectfully requested in a letter that CVM and FDA delay enforcement of GFI #256 until at least FY2024.
FOLLOW US
